Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

¿Te ayudamos?

Ejemplos de búsqueda

Vídeos Explicativos

GALILEO

Financiado

Cerrado

The first wide range flow sensor to unlock microfluidic cell analyses for precli...

The first wide range flow sensor to unlock microfluidic cell analyses for preclinical studies There is a critical need to improve the diagnosis, drug discovery and development pipeline to increase the success rate of new therapeutics (as low as 3.4% for cancer drugs) and provide earlier detection and treatment. Microfluidi... ver más

30/04/2025

ELVESYS

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

ELVESYS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2025-04-30

HORIZON-EIC-2022-TRANSITIONOPEN-01: EIC Transition Open 2022 Expected Impact:At the end of the EIC Transition project, it should be ready for the next stage, whi...

I+D

Cerrada

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

ELVESYS

1.67M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 25 meses Fecha Inicio: 2023-03-28
Fecha Fin: 2025-04-30

Líder del proyecto

ELVESYS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto There is a critical need to improve the diagnosis, drug discovery and development pipeline to increase the success rate of new therapeutics (as low as 3.4% for cancer drugs) and provide earlier detection and treatment. Microfluidic cell-based assays and analyses are one of the most promising strategies, supported by direct feedback from industry and regulatory agencies. Integrated microscale fluidics adds an extra dimension to in vitro cell cultures and is an enabling technology of single cell analyses and nanotherapies. However, the main limitations with these platforms expressed by our clients from academia and industry are their inability to measure and control flow rate over a wide enough range (100-times too narrow), imprecision and failure to detect sensor drift that leads to experimental error. Our GALILEO flow sensor innovation demonstrates the technical ability to address these pressing requirements for microfluidic cell assays and analyses. This proposal will advance the proof of concept to a viable demonstrator of the technology for beta testing. The timing is ideal for our solution: expressed end user demand is high and legislative bodies have voted to reduce animal testing by 2035. GALILEO has strong competitive advantage in the microfluidic flow sensor market with a SAM of 535 mil EUR/year, increasing with the growth of next-generation sequencing and genomic medicine. Elvesys is an entrepreneur-led microfluidics instrument company with demonstrated success in the development and commercialisation of 15 instruments for microfluidic flow control, and the generation of 10 growing spin-offs in the last 11 years. Our end user feedback and iterative testing approach to innovation puts us in a position of strength to execute an optimal product-market fit, targeting market creation. We have the proven technical expertise to deliver on GALILEO performance, and the market contact breadth to disseminate, exploit and communicate the technology to all stakeholders.

Conecta tu I+D

Entra hoy

Forgot your password?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores